Loading…
← CockpitCompetitor Analysis › KPL.NS Kwality Pharmaceuticals LtdOpen in the cockpit ↗

Kwality Pharmaceuticals LtdKPL.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 98
Mkt cap
$467M
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$2.40M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+7.5 pp
WACC 12.3%
Hurdle
n/a
no reverse DCF
Close · INR₹4,208
1D+4.0%
1W+5.6%
1M+25.0%
3M+19.1%
6M+110.3%
YTDn/a
1Yn/a
ATR %5.3%
52w lowhigh0.6% off high

What Kwality Pharmaceuticals does

Employees: 1,137

Kwality Pharmaceuticals at a glance

Size Kwality Pharmaceuticals (KPL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $467M, the 877th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹4,208 on 18 Nov 2026.

Performance Over six months the shares gained 110.3%, against -8.3% for the median peer and +3.8% for the India market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 47.7% over the last twelve months (peer median +12.5%); the operating margin is 22.3% (peer median 0.1%).

Valuation It trades at 7.2× enterprise value to sales against a peer median of 4.6× (7th most expensive of 19).

Capital Return on invested capital runs 7.5 points above its cost of capital (12.3% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026KPL.NS 205Peer median 93
Six months, rebased to 100: Kwality Pharmaceuticals against the median of its 20 peers (local-currency closes).

Kwality Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹6.24B₹5.03B₹3.70B₹3.07B₹2.51B
Revenue growth—+36%+21%+22%—
Gross profit₹2.22B₹1.44B₹999M₹750M₹754M
EBITDA₹1.60B₹1.21B₹834M₹696M₹630M
Net income₹960M₹673M₹398M₹238M₹194M
Free cash flown/a-₹387M₹188M₹24.7M-₹61.7M
Capital expendituren/a₹489M₹288M₹306M₹504M
Total debt₹1.46B₹1.31B₹1.12B₹981M₹903M

Quarterly statements and history in the cockpit →

Kwality Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%CAPR002370EOLS66200026933012013705AQSTASMBSMSPHARMAHNSARGNX688373GUFICBIO003020300584KPL.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Kwality Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×10×20×002370EOLS66200026933012013705AQSTASMBSMSPHARMA600624HNSARGNX688373GUFICBIO603566300584000640KPL.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kwality Pharmaceuticals is the large dot.

Kwality Pharmaceuticals competitors and peer comparison

How Kwality Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kwality Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureKPL.NSPeer medianRank in peer set
1-month return+25.0%-3.2%2nd highest of 21
6-month return+110.3%-8.3%highest of 20
Distance from 52-week high-0.6%-38.2%highest of 21
Revenue growth (TTM)+47.7%+12.5%3rd highest of 20
Operating margin22.3%0.1%2nd highest of 19
EV / Sales7.2×4.6×7th most expensive of 19
ROIC minus cost of capital+7.5 pp-5.4 pphighest of 17
EV / EBITDA28.2×17.7×most expensive of 5
Net debt / EBITDA0.9×1.8×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%

Questions

Which companies are Kwality Pharmaceuticals's closest peers?
The cockpit's peer set: Capricor Therapeutics (CAPR), Zhejiang Yatai Pharmaceutical (002370.SZ), Evolus (EOLS), Handa Pharmaceuticals (6620.TWO), Hainan Shuangcheng Pharmaceuticals (002693.SZ), BlossomHill Therapeutics (BLSM), ChengDa PharmaCeuticals (301201.SZ), YungShin Global (3705.TW).
Is Kwality Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 7.2× against a peer median of 4.6×, 7th most expensive of 19 in its peer set.
How has Kwality Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +110.3% against -8.3% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.